Anti-MUC1, Recombinant [SM3]
Invented by Prof Joyce Taylor-Papadimitriou from King's College London , Prof Joy Burchell from King's College London
- References (2)
- Inventor Info
|Applications||ELISA FACS IHC|
|Antigen/Gene or Protein Targets||Mucin1 (MUC1)|
|Synonyms||ADMCKD, ADMCKD1, Breast carcinoma associated antigen DF3, Breast carcinoma-associated antigen DF3, CA 15-3, CA15 3, CA15 3 antigen, CA15.3, Cancer antigen 15-3, Carcinoma associated mucin, Carcinoma-associated mucin, CD 227, CD227|
|Relevance||MUC1 is a large cell surface mucin glycoprotein expressed by most glandular and ductal epithelial cells and some hematopoitic cell lineages. In the vast majority of human carcinomas, this protein is upregulated, poorly glycosylated and appears on the cell surface in a non-polarised fashion. SM3 antibody recognises this under-glycosylated form of MUC1 and is therefore tunour specific and may be relevant for breast cancer therapy. SM3 also detects MUC1 within colon and ovarian cancer and most adenocarcinomas and may be used for immunohistochemistry (reactive with methacarn fixed tissue), and immunotargeting.|
|Immunogen||Hydrogen fluoride deglycosylated milk mucin.|
|Positive Control||Ovarian, breast or colon carcinoma, normal intestine or colon|
|Research Area||Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction|
The product of the MUC1 gene is the polymorphic epithelial mucin. SM3 reacts with a core protein epitope defined as PDTRP.
Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.
*** PLEASE NOTE: Applications stated are those corresponding to original hybridoma ***
There are 2 reference entries for this reagent.View All References